[go: up one dir, main page]

WO2003027276A3 - Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia - Google Patents

Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia Download PDF

Info

Publication number
WO2003027276A3
WO2003027276A3 PCT/IB2002/004134 IB0204134W WO03027276A3 WO 2003027276 A3 WO2003027276 A3 WO 2003027276A3 IB 0204134 W IB0204134 W IB 0204134W WO 03027276 A3 WO03027276 A3 WO 03027276A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoma
leukemia
diagnosis
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/004134
Other languages
French (fr)
Other versions
WO2003027276A2 (en
Inventor
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Anne Ahlmann Nielsen
Helle Moving
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Priority to AU2002337442A priority Critical patent/AU2002337442A1/en
Publication of WO2003027276A2 publication Critical patent/WO2003027276A2/en
Publication of WO2003027276A3 publication Critical patent/WO2003027276A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel sequences for use in diagnosis and treatment of lymphoma and leukemia. In addition, the present invention describes the use of novel compositions for use in screening methods.
PCT/IB2002/004134 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia Ceased WO2003027276A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002337442A AU2002337442A1 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/962,916 2001-09-24
US09/962,854 2001-09-24
US09/962,855 2001-09-24
US09/962,929 2001-09-24
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/963,131 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Publications (2)

Publication Number Publication Date
WO2003027276A2 WO2003027276A2 (en) 2003-04-03
WO2003027276A3 true WO2003027276A3 (en) 2004-02-12

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 Ceased WO2003027321A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
PCT/IB2002/004197 Ceased WO2003027295A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of jak1
PCT/IB2002/005830 Ceased WO2003043565A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
PCT/IB2002/004123 Ceased WO2003027320A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
PCT/IB2002/004134 Ceased WO2003027276A2 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 Ceased WO2003027321A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
PCT/IB2002/004197 Ceased WO2003027295A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of jak1
PCT/IB2002/005830 Ceased WO2003043565A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
PCT/IB2002/004123 Ceased WO2003027320A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1

Country Status (2)

Country Link
AU (4) AU2002364889A1 (en)
WO (5) WO2003027321A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959969A2 (en) * 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
CA2642266A1 (en) * 2006-02-14 2007-08-23 President And Fellows Of Harvard College Mitotic progression genes and methods of modulating mitosis
WO2020247914A1 (en) * 2019-06-07 2020-12-10 Emory University Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016430A1 (en) * 1990-04-13 1991-10-31 Research Development Foundation NOVEL T-CELL LYMPHOMA cDNA CLONES
WO1993015221A1 (en) * 1992-01-29 1993-08-05 Hitachi Chemical Co., Ltd. Method for measuring messenger rna
WO1998016557A1 (en) * 1996-10-11 1998-04-23 The General Hospital Corporation Assays for g-protein-linked receptors
WO1999054448A2 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences, increased expression thereof in uterus myoma tissue
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO2001000861A1 (en) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Antisense modulation of g-alpha-s1 expression
WO2001007617A1 (en) * 1999-07-22 2001-02-01 Knoll Gmbh Human homologue of bovine neuroendocrine secretory protein, nesp55, polynucleotides and uses thereof linked with obesity
WO2002022882A2 (en) * 2000-09-13 2002-03-21 Archemix Corporation Target activated nucleic acid biosensor and methods of using same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
AU6407696A (en) * 1995-07-07 1997-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of identifying inhibitors of the jak-stat signal transduction pathway
WO1998020126A1 (en) * 1996-11-01 1998-05-14 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
CA2290738A1 (en) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Nucleic acid arrays
EP1053319A2 (en) * 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
CA2321132A1 (en) * 1998-02-23 1999-08-26 Andrei V. Gudkov P53-dependent secretion of growth inhibitory factors
ES2222705T3 (en) * 1998-04-17 2005-02-01 Parker Hughes Institute BTK INHIBITORS AND METHODS FOR IDENTIFICATION AND USE.
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
AU2200900A (en) * 1998-12-22 2000-07-12 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative disorders
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1226280A4 (en) * 1999-10-25 2003-10-15 Univ Princeton GENETIC SEQUENCES ASSOCIATED WITH NEURAL CELL PROLIFERATION AND DISEASES
WO2001034633A2 (en) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening for active agents
CA2395607A1 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
IL151079A0 (en) * 2000-02-07 2003-04-10 Quark Biotech Inc Fas pathway genes
HRP20020838A2 (en) * 2000-04-25 2004-12-31 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
KR100830859B1 (en) * 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 Imidazopyridine derivatives and pharmaceutical compositions containing the same
US20020040127A1 (en) * 2000-06-09 2002-04-04 Yuqiu Jiang Compositions and methods for the therapy and diagnosis of colon cancer
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
AU2001290699A1 (en) * 2000-09-08 2002-03-22 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
EP1362122A2 (en) * 2000-09-12 2003-11-19 TransGenetics Incorporated Microarrayed organization of transcription factor target genes
WO2002040637A2 (en) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Methods of inhibiting kinases
DE60232059D1 (en) * 2001-03-01 2009-06-04 Epigenomics Ag METHOD FOR DEVELOPING SKILLS FOR DIAGNOSTIC AND THERAPEUTIC USES BASED ON THE EXPRESSION AND METHYLATION STATUS OF THE GENES
WO2003025138A2 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016430A1 (en) * 1990-04-13 1991-10-31 Research Development Foundation NOVEL T-CELL LYMPHOMA cDNA CLONES
WO1993015221A1 (en) * 1992-01-29 1993-08-05 Hitachi Chemical Co., Ltd. Method for measuring messenger rna
WO1998016557A1 (en) * 1996-10-11 1998-04-23 The General Hospital Corporation Assays for g-protein-linked receptors
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO1999054448A2 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences, increased expression thereof in uterus myoma tissue
WO2001000861A1 (en) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Antisense modulation of g-alpha-s1 expression
WO2001007617A1 (en) * 1999-07-22 2001-02-01 Knoll Gmbh Human homologue of bovine neuroendocrine secretory protein, nesp55, polynucleotides and uses thereof linked with obesity
WO2002022882A2 (en) * 2000-09-13 2002-03-21 Archemix Corporation Target activated nucleic acid biosensor and methods of using same

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HALLEK M ET AL: "REDUCED RESPONSIVENESS OF ADENYLATE CYCLASE TO FORSKOLIN IN HUMAN LYMPHOMA CELLS", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 42, no. 7, 1991, pages 1329 - 1334, XP008011750, ISSN: 0006-2952 *
HAYWARD B E ET AL: "AN IMPRINTED ANTISENSE TRANSCRIPT AT THE HUMAN GNAS1 LOCUS", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 5, 22 March 2000 (2000-03-22), pages 835 - 841, XP000946068, ISSN: 0964-6906 *
KLEMKE MARTIN ET AL: "Characterization of the extra-large G protein alpha-subunit XLalphas. II. Signal transduction properties.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33633 - 33640, XP002247467, ISSN: 0021-9258 *
LAZAREVIC M B ET AL: "Glucocorticoid-altered G protein alpha subunit expression in jurkat lymphoma cells.", CLINICAL RESEARCH, vol. 42, no. 2, 1994, Meeting of the American Federation for Clinical Research;Baltimore, Maryland, USA; April 29-May 2, 1994, pages 311A, XP008019515, ISSN: 0009-9279 *
MATTERA R ET AL: "IDENTIFICATION BY MOLECULAR CLONING OF TWO FORMS OF THE ALPHA-SUBUNIT OF THE HUMAN LIVER STIMULATORY G-S REGULATORY COMPONENT OF ADENYLYL CYCLASE", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 206, no. 1, 1986, pages 36 - 42, XP001159666, ISSN: 0014-5793 *
PFEILSTOECKER M ET AL: "Hematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Galpha 16 and CD34.", AMERICAN JOURNAL OF HEMATOLOGY, vol. 64, no. 3, July 2000 (2000-07-01), pages 156 - 160, XP008019516, ISSN: 0361-8609 *
RALL T ET AL: "IDENTIFICATION OF THE LESION IN THE STIMULATORY GTP-BINDING PROTEIN OF THE UNCOUPLED S49 LYMPHOMA", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 224, no. 2, 1987, pages 365 - 371, XP001159774, ISSN: 0014-5793 *
WEISS U ET AL: "NEUROENDOCRINE SECRETORY PROTEIN 55 (NESP55): ALTERNATIVE SPLICING ONTO TRANSCRIPTS OF THE GNAS GENE AND POSTTRANSLATIONAL PROCESSING OF A MATERNALLY EXPRESSED PROTEIN", NEUROENDOCRINOLOGY, S.KARGER, BASEL, CH, vol. 71, no. 3, 2000, pages 177 - 186, XP000938251, ISSN: 0028-3835 *
WROE STEPHANIE F ET AL: "An imprinted transcript, antisense to Nesp, adds complexity to the cluster of imprinted genes at the mouse Gnas locus.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 7, 28 March 2000 (2000-03-28), March 28, 2000, pages 3342 - 3346, XP000938372, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003043565A3 (en) 2003-11-13
WO2003027295A3 (en) 2003-10-16
AU2002337442A1 (en) 2003-04-07
WO2003027321A3 (en) 2003-11-06
WO2003027276A2 (en) 2003-04-03
AU2002330713A1 (en) 2003-04-07
AU2002364889A1 (en) 2003-06-10
WO2003027295A2 (en) 2003-04-03
WO2003027320A3 (en) 2003-10-23
WO2003027320A2 (en) 2003-04-03
AU2002364889A8 (en) 2003-06-10
AU2002329000A1 (en) 2003-04-07
WO2003027321A2 (en) 2003-04-03
WO2003043565A2 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2003008583A3 (en) Novel compositions and methods for cancer
EP2014669A3 (en) Compositions and methods for cancer
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
EP2772254A3 (en) Novel Antibacterial Agents
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
GB0111186D0 (en) Novel compounds
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
MXPA03007126A (en) Parasiticidal compositions and methods of use.
WO2003035837A3 (en) Novel compositions and methods for cancer
CA2436572A1 (en) Perylenequinones for use as photosensitizers and sonosensitizers
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2003039484A3 (en) Novel compositions and methods for cancer
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2003071933A3 (en) Novel compositions and methods for cancer
WO2003027276A3 (en) Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
IL175369A0 (en) Novel compound, corresponding compositions, preparation and/or treatment methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP